Bioxcel Therapeutics
BTAI
Bioxcel Therapeutics (BTAI) news
Recent news
BioXcel Therapeutics - Deal with Teva includes $57.5 mln cash, up to $67.5 mln development milestones, $20 mln commercial milestones - SEC filing
AInvest Wire · 3d agoBioxcel secures $19M dip financing from existing lenders
Bioxcel Therapeutics has secured $19 million in debt-in-place (DIP) financing from its existing lenders to support ongoing operations amid its restructuring process. The financing, announced in recent filings, allows the company to continue its business while it navigates financial challenges and…
AInvest Wire · 3d agoBioxcel Therapeutics - Igalmi remains commercially available; supply to continue during sale process
AInvest Wire · 3d agoBioXcel Therapeutics - Commences voluntary chapter 11 proceedings in U.S. bankruptcy court
AInvest Wire · 3d agoImportantBioxcel Therapeutics - Secures $19 mln in DIP financing from existing secured lenders
AInvest Wire · 3d agoLight Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.